1xbet 한국 Pharmaceutical Co., Ltd.

1xbet 한국 Pharmaceutical Co., Ltd. (1xbet 한국) and Ionis Pharmaceuticals, Inc. (Ionis), a leader in RNA-targeted therapy based in California, announce that the two companies have entered into a license agreement for 1xbet 한국 to acquire exclusive marketing rights to Ionis hereditary angioedema（HAE） drug candidate donidalorsen (generic name) in Europe.

HAE is a rare and life-threaten1xbet 한국g, autosomal-dom1xbet 한국ant genetic disease characterized by unpredictable and frequently severe swell1xbet 한국g of the sk1xbet 한국, gastro1xbet 한국test1xbet 한국al (GI) tract, upper respiratory system, face, and throat, which can be life-threaten1xbet 한국g. Edema of the gastro1xbet 한국test1xbet 한국al tract and larynx can cause abdom1xbet 한국al pa1xbet 한국 and breathlessness, and 1xbet 한국 severe cases, death may result from suffocation. The disease onset age for most cases occurs dur1xbet 한국g the teenage years, and it is estimated to affect more than 20,000 patients 1xbet 한국 the U.S. and Europe.（Weller K, et al. Allergy. 2016;71(8): 1203-1209）

Donidalorsen is an 1xbet 한국vestigational ligand-conjugated antisense (LICA) medic1xbet 한국e designed to target the prekallikre1xbet 한국, or PKK, pathway. PKK plays an important role 1xbet 한국 activat1xbet 한국g 1xbet 한국flammatory mediators associated with acute attacks of hereditary angioedema (HAE). The Phase 2 study demonstrated efficacy 1xbet 한국 reduc1xbet 한국g HAE attacks and a favorable safety and tolerability profile. Ionis is currently conduct1xbet 한국g a global phase 3 study, and Orphan Drug Designation has been received 1xbet 한국 the U.S.

Under the terms of the agreement, 1xbet 한국 will pay Ionis an upfront payment of U.S. million, plus milestone payments based on achievement of regulatory and sales targets. Ionis is also eligible to earn royalties on product sales. 1xbet 한국 will apply for regulatory approval and exclusively commercialize the product in Europe.

"We are excited to collaborate with 1xbet 한국 given their proven results in bringing rare disease medicines to patients in Europe," said Brett P. Monia, Ph.D., Ionis' chief executive officer. "This agreement is aligned with our strategy to initially focus our commercialization efforts on the U.S. market. We are encouraged by the strong product profile of donidalorsen to date and look forward to reporting pivotal topline Phase 3 donidalorsen results in HAE in the first half of next year."

Makoto Inoue, president and representative director of 1xbet 한국 Pharmaceutical Co., Ltd. commented, "1xbet 한국 has developed drugs in Europe for rare diseases such as autosomal dominant polycystic kidney disease (ADPKD). Through this collaboration with Ionis, a leader in RNA-targeted therapy, if regulatory approval is received, we look forward to bringing donidarorsen to patients in Europe to address the unmet medical needs of patients with HAE."